Arkolith/Insider Trading/IKT/Form 4

Kush Arvind

DirectorInhibikase Therapeutics, Inc. (IKT) · full profile →Form 4 · filed Oct 23, 2024
Net Buying
Open-Market Buys
$199K
Open-Market Sells
$0
Net Open-Market Flow
$199K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 21, 2024Buy(P)145K$1.37$199K145K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 21, 2024Grant(A)60K—$060K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-116783) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML